IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
Abstract
Interleukin-1 receptor antagonist (IL-1ra) has been shown to play a crucial role in the prevention of various inflammatory diseases. There is also convincing evidence that IL-1ra is able to counteract inflammatory effects of IL-1 members implicated in insulin resistance and diabetes. However, the use of knock-out animal models provides evidence to the contrary and the role of IL-1ra in obesity-linked anomalies remains controversial. This minireview gets an insight into recent findings on the implication of IL-1ra and its gene polymorphism in diabetes and obesity, discusses the potential dual effects of IL-1ra observed in different models, and comments on future directions.
- Publication:
-
FEBS Letters
- Pub Date:
- January 2006
- DOI:
- 10.1016/j.febslet.2006.10.061
- Bibcode:
- 2006FEBSL.580.6289P
- Keywords:
-
- IL-1ra;
- interleukin-1 receptor antagonist;
- TNF-α;
- tumor necrosis factor alpha;
- IFNγ;
- interferon gamma;
- PPARγ;
- peroxisome proliferator-activated receptor gamma;
- NF-κB;
- nuclear factor kappa B;
- NOD;
- non-obese diabetic;
- WAT;
- white adipose tissue;
- Interleukin-1 receptor antagonist;
- Diabetes;
- Obesity;
- Insulin resistance;
- Gene polymorphism;
- Adipocyte